Wells Fargo & Company MN Has $78,000 Stock Holdings in InfuSystem Holdings, Inc. (NYSE:INFU)

Wells Fargo & Company MN grew its position in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 51.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,286 shares of the company’s stock after acquiring an additional 3,165 shares during the quarter. Wells Fargo & Company MN’s holdings in InfuSystem were worth $78,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Legato Capital Management LLC bought a new stake in InfuSystem in the 4th quarter valued at $85,000. Summit Global Investments acquired a new stake in shares of InfuSystem during the 4th quarter worth $86,000. Sei Investments Co. acquired a new stake in InfuSystem in the fourth quarter valued at about $90,000. JPMorgan Chase & Co. boosted its stake in InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after buying an additional 6,623 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in InfuSystem in the fourth quarter valued at about $164,000. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Stock Up 2.0%

INFU stock opened at $5.48 on Tuesday. The stock’s fifty day simple moving average is $5.27 and its two-hundred day simple moving average is $7.15. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 1-year low of $4.61 and a 1-year high of $9.97. The stock has a market cap of $115.17 million, a P/E ratio of 91.35 and a beta of 1.73.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Sidoti upgraded InfuSystem to a “strong-buy” rating in a research report on Tuesday, March 18th. B. Riley upgraded InfuSystem to a “strong-buy” rating in a report on Thursday, May 8th. Finally, StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 14th.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.